Tessera
Folgen

Marleen Kok, MD PhD, NKI

@marleenkok.bsky.social

Breast Oncologist and translational researcher @nki, Immunotherapy and immune cell lover, Mother, 🍀🌿

28 Posts996 Follower155 Folgt
Marleen Kok, MD PhD, NKI@marleenkok.bsky.social · last yr.

More than proud to be working @nkinl.bsky.social under the great leadership of @thijnbrummel.bsky.social. His achievements in the field of fundamental sciences ✍️🔬are truly amazing! Congrats Thijn🥳

Netherlands Cancer Institute @nkinl.bsky.social · last yr.

Proud! 💙 Our scientific director Thijn Brummelkamp receives the Spinoza Prize, a prize for scientists who belong to the best researchers worldwide. A wonderful recognition for his groundbreaking research. Congrats Thijn! 🎉 @thijnbrummel.bsky.social Full article ➡️ bit.ly/40p4KnK

Marleen Kok, MD PhD, NKI@marleenkok.bsky.social · last yr.

Please donate!🚵🏽‍♂️💵💰 Last year we received a huge grant 🤩from KWF to launch the internat OPTImaL trial to avoid chemo for low stage BC with many immune cells! We strongly feel that we should do something in return for KWF so we will bike 🚵🏽‍♂️the Alpe d’Huez 💪🏼 www.opgevenisgeenoptie.nl/fundraisers/...

Marleen Kok

Ik doe mee aan Alpe d’HuZes omdat ik geloof dat wij samen kunnen werken aan een wereld waarin je niet meer doodgaat aan kanker, wil jij mij steunen?

opgevenisgeenoptie.nl

Marleen Kok, MD PhD, NKI@marleenkok.bsky.social · 2y ago

Looking forward to work as senior editor for the @theaacr.bsky.social journal Clin Cancer Res with this 👇 amazing editor-in-chief. Congrats Tim Yap!

American Association for Cancer Research (AACR)@theaacr.bsky.social · 2y ago

Timothy A. Yap, MBBS, PhD, has been appointed editor-in-chief of the AACR journal Clinical Cancer Research. Dr. Yap is co-director for the AACR/ASCO Methods in Clinical Cancer Research Workshop and a past cochair of the AACR Annual Meeting Clinical Trials Committee. www.aacr.org/about-the-aa...

Marleen Kok, MD PhD, NKI@marleenkok.bsky.social · 2y ago

Important editorial in the @thelancet.bsky.social Wrong decisions endanger Health care in the US and worldwide, especially for people who need it the most! Lets unit and speak up!📣 www.thelancet.com/journals/lan...

American chaos: standing up for health and medicine

Withdrawal from WHO and the Paris Agreements. USAID shuttered and aid halted, ceasing health programmes globally. A freeze on US$3 trillion worth of federal grants and loans, jeopardising the function...

thelancet.com

E John Wherry@ejohnwherry.bsky.social · 2y ago

This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this? grants.nih.gov/grants/guide...

NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates

NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD

grants.nih.gov

Marleen Kok, MD PhD, NKI@marleenkok.bsky.social · 2y ago

very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm

Dana-Farber’s Breast Oncology Center@dfcibreastonc.bsky.social · 2y ago

📢 Just published! A phase II study of #abemaciclib for patients with #retinoblastoma-positive, triple-negative #metastatic breast cancer. 🔓https://pubmed.ncbi.nlm.nih.gov/39908010/ @drtimothyerick.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social

Marleen Kok, MD PhD, NKI@marleenkok.bsky.social · 2y ago

Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️

Sherene Loi MD@loisher.bsky.social · 2y ago

summary CM-7FL @oncoalert.bsky.social @naturemedicine.bsky.social link: rdcu.be/d8Cw4. Here Nivo ⬆️ pCR rates in high grade HR+ BC. Increasing pCR rates in this subtype is HARD! PD-L1+ & #TIL higher pCR. This study will change how we think about HR+BC- some are immunogenic & need PD-1i with chemo

Jon Lim, FRCP PhD@drjonlim.bsky.social · 2y ago

Big fan of the concept of immunogenic cell death/inducing immunogenicity with 'conventional' therapies - so really looking forward to reading/hearing more about TONIC2 following the nice work from the original TONIC trial by @marleenkok.bsky.social & team @nkinl.bsky.social 👇

Marleen Kok, MD PhD, NKI@marleenkok.bsky.social · 2y ago

Exciting to present 🎤 new data #SABCS24 from TONIC2 study, follow-up from rdcu.be/d22kf. Do immune inductions using low dose dox or cisplatin indeed benefit pts? See us at P1-7-30 and during PS17-9 we show data on TME during acquired resistance to aPD1. With V. Geurts @nkinl.bsky.social @oncoalert

Marleen Kok, MD PhD, NKI@marleenkok.bsky.social · 2y ago

Exciting to present 🎤 new data #SABCS24 from TONIC2 study, follow-up from rdcu.be/d22kf. Do immune inductions using low dose dox or cisplatin indeed benefit pts? See us at P1-7-30 and during PS17-9 we show data on TME during acquired resistance to aPD1. With V. Geurts @nkinl.bsky.social @oncoalert

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Nature Medicine - A pick-the-winner clinical trial design in patients with metastatic triple-negative breast cancer shows that immune induction with doxorubicin or cisplatin may improve clinical...

rdcu.be